Refine Search

Search Results -

Terms	Documents
oulleyaconinitine	0

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L5	E	5.5 % OF 11.5%
	Ž	Refine Search
Recall Text	Clear	Interrupt

Search History

DATE: Thursday, September 16, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB	USPT, USOC, EPAB, JPAB, DWPI; PLUR=1	YES; OP=ADJ	
<u>L5</u>	bulleyaconinitine	0	<u>L5</u>
<u>L4</u>	3-acetylaconitine	0	<u>L4</u>
<u>L3</u>	L1 same (pain or inflamm\$)	. 1	<u>L3</u>
<u>L2</u>	L1 and (pain or inflamm\$)	3	<u>L2</u>
<u>L1</u>	lappaconitine	13	<u>L1</u>

END OF SEARCH HISTORY

```
NEWS
                  Web Page URLs for STN Seminar Schedule - N. America
NEWS
                  "Ask CAS" for self-help around the clock
NEWS
                 EXTEND option available in structure searching
         May 12
NEWS
         May 12
                 Polymer links for the POLYLINK command completed in REGISTRY
                 New UPM (Update Code Maximum) field for more efficient patent
NEWS
         May 27
                  SDIs in CAplus
NEWS
                 CAplus super roles and document types searchable in REGISTRY
         May 27
NEWS
      7
         Jun 28
                 Additional enzyme-catalyzed reactions added to CASREACT
NEWS
                 ANTE, AQUALINE, BIOENG, CIVILENG, ENVIROENG, MECHENG,
      8
         Jun 28
                 and WATER from CSA now available on STN(R)
NEWS
         Jul 12
                 BEILSTEIN enhanced with new display and select options,
                 resulting in a closer connection to BABS
NEWS 10
         Jul 30
                 BEILSTEIN on STN workshop to be held August 24 in conjunction
                 with the 228th ACS National Meeting
NEWS 11
         AUG 02
                 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
                 fields
NEWS 12
         AUG 02
                 CAplus and CA patent records enhanced with European and Japan
                 Patent Office Classifications
NEWS 13
         AUG 02
                 STN User Update to be held August 22 in conjunction with the
                 228th ACS National Meeting
NEWS 14
         AUG 02
                 The Analysis Edition of STN Express with Discover!
                 (Version 7.01 for Windows) now available
                 Pricing for the Save Answers for SciFinder Wizard within
NEWS 15
         AUG 04
                 STN Express with Discover! will change September 1, 2004
NEWS 16
                 BIOCOMMERCE: Changes and enhancements to content coverage
         AUG 27
                 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
NEWS 17
         AUG 27
                 status data from INPADOC
         SEP 01
NEWS 18
                 INPADOC: New family current-awareness alert (SDI) available
NEWS 19
         SEP 01
                 New pricing for the Save Answers for SciFinder Wizard within
                 STN Express with Discover!
NEWS 20
         SEP 01
                 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 21
         SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS EXPRESS
              JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
              MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
              AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
              STN Operating Hours Plus Help Desk Availability
NEWS HOURS
NEWS INTER
              General Internet Information
NEWS LOGIN
              Welcome Banner and News Items
              Direct Dial and Telecommunication Network Access to STN
NEWS PHONE
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 20:20:36 ON 16 SEP 2004

=> file bioscience FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.21 0.21

FULL ESTIMATED COST

FILE 'ADISCTI' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Adis Data Information BV

120 - 11

FILE 'AGRICOLA' ENTERED AT 20:20:45 ON 16 SEP 2004

FILE 'AQUALINE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 20:20:45 ON 16 SEP 2004 Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 20:20:45 ON 16 SEP 2004 Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 20:20:45 ON 16 SEP 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 20:20:45 ON 16 SEP 2004

FILE 'CAPLUS' ENTERED AT 20:20:45 ON 16 SEP 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 20:20:45 ON 16 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 20:20:45 ON 16 SEP 2004

COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

L. ...

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 20:20:45 ON 16 SEP 2004

FILE 'FOMAD' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 20:20:45 ON 16 SEP 2004

FILE 'HEALSAFE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

.

FILE 'JICST-EPLUS' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 20:20:45 ON 16 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 20:20:45 ON 16 SEP 2004 Compiled and distributed by the NTIS, U.S. Department of Commerce. It contains copyrighted material. All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 20:20:45 ON 16 SEP 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 20:20:45 ON 16 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 20:20:45 ON 16 SEP 2004 Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 20:20:45 ON 16 SEP 2004 Copyright (c) 2004 The Thomson Corporation.

, John ...

FILE 'SYNTHLINE' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 20:20:45 ON 16 SEP 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 20:20:45 ON 16 SEP 2004 CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 20:20:45 ON 16 SEP 2004 COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s (lappaconitine or 3-acetylaconitine or bulleyaconinitine) (P) (pain or inflamm?) PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' 26 FILES SEARCHED... PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN'

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' 52 FILES SEARCHED... PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN' PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH FIELD CODE - 'AND' OPERATOR ASSUMED 'ONINITINE) (P) (PAIN'

71 (LAPPACONITINE OR 3-ACETYLACONITINE OR BULLEYACONINITINE) (P) (PAI N OR INFLAMM?)

=> dup rem l1 DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE PROCESSING COMPLETED FOR L1

=> d ibib abs 12 1-23

ANSWER 1 OF 23 WPLDS COPYRIGHT 2004 THOMSON DERWENT on STN

23 DUP REM L1 (48 DUPLICATES REMOVED)

2004-227392 [22] WPIDS ACCESSION NUMBER:

C2004-089633 DOC. NO. CPI:

TITLE: New medicine for anti-cancer, anti-AIDs and giving-up

drug habits and its preparing and applying method.

DERWENT CLASS:

INVENTOR(S): HAN, S

PATENT ASSIGNEE(S): (HANS-I) HAN S

COUNTRY COUNT:

PATENT INFORMATION:

KIND DATE LA PG PATENT NO WEEK -----CN 1391942 A 20030122 (200422)*

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
CN 1391942	Α	CN 2002-129190	20020820

PRIORITY APPLN. INFO: CN 2002-129190 20020820

2004-227392 [22] ΑN WPIDS

AΒ 1391942 A UPAB: 20040331

> NOVELTY - The present invention relates to a kind of compound taxol preparation for treating cancer and AIDS and giving up drug habits. Materials including taxol, harringtonine, Bakatine III, lappaconitine, musk, etc. are prepared through supercritical CO2 extraction, concentration, separation of effective components and other steps into compound taxol injection, compound taxol capsule and compound taxolplaster. The present invention has the functions of stopping pain, eliminating tumor and other treating effects and no toxic side effect.

Dwg.0/0

administered 3 hr after i.p. reserpine (3 mg/kg). However, 120 hr after reserpine, the analgesic effect of LA or DL was restored. Concomitant administration of tryptophan or 5-HT as well as premedication of methyldopa prevented reserpine-induced decrease of LA or DL analgesia. 5-HT (i.c.v.) enhanced the analgesia of LA and DL. LA or DL-induced analgesia was attenuated by pretreatment with CP but this attenuation was reversed by i.c.v. 5-HT. Chloroamphetamine also markedly reduced LA and DL-induced analgesia. (AS)

L2 ANSWER 16 OF 23 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on

STN DUPLICATE 6

ACCESSION NUMBER: 1988:443533 BIOSIS

DOCUMENT NUMBER: PREV198886095631; BA86:95631

TITLE: PHARMACOLOGICAL STUDIES OF LAPPACONITINE ANALGESIC

ACTIVITIES.

AUTHOR(S): ONO M [Reprint author]; SATOH T

CORPORATE SOURCE: DEP PHARMACOL TOXICOL, TOKYO COLL PHARM, 1432-1 HORINOUCHI,

HACHIOJI, TOKYO 192-03, JPN

SOURCE: Arzneimittel-Forschung, (1988) Vol. 38, No. 7, pp. 892-895.

CODEN: ARZNAD. ISSN: 0004-4172.

DOCUMENT TYPE: Article FILE SEGMENT: BA LANGUAGE: ENGLISH

ENTRY DATE: Entered STN: 4 Oct 1988

Last Updated on STN: 4 Oct 1988

The analgesic activity of lappaconitine, which is contained in the root of Aconitum sinomantanum Nakai, was examined after oral and subcutaneous administration to mice or rats by using methods for screening of analgesics, i.e., hot plate, tail immersion, tail pinch, tail pressure, acetic acid-induced writhing, bradykinin-induced flexor reflex of hind limb and Randall-Selitto methods. The results were compared with those for morphine, indometacin and acetylsalicyclic acid (ASA). Analgesic activities of lappacontinine were greater than those of indometacin and ASA, but generally about 2 to 5 times less than those of morphine. However, in the rat tail immersion test, orally administered lappaconitine exhibited more potent analgesic activity than morphine; in this test, lappaconitine was almost equipotent when given orally and subcutaneously, whereas the potency of orally administered morphine was only one-twentieth of that of subcutaneously administered morphine. Like morphine, lappacontinine increased the pain threshold of the normal paw as well as that of the inflamed paw when tested by the Randall-Selitto method. The results show that lappaconitine has strong analgesic activity, and further suggest that the central nervous system may be involved in the action on the pain threshold.



ANSWER 17 OF 23 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 7

ACCESSION NUMBER: 1987:383589 BIOSIS

DOCUMENT NUMBER: PREV198784070086; BA84:70086

TITLE: ANTI-INFLAMMATORY AND ANALGESIC ACTIVITIES OF N

DEACETYLLAPPACONITINE AND LAPPACONITINE.

AUTHOR(S): LIU J-H [Reprint author]; ZHU Y-X; TANG X-C

CORPORATE SOURCE: SHANGHAI INST MATERIA MEDICA, CHIN ACAD SCI, SHANGHAI

200031

SOURCE: Acta Pharmacologica Sinica, (1987) Vol. 8, No. 4, pp.

301-305.

CODEN: CYLPDN. ISSN: 0253-9756.

DOCUMENT TYPE: Article

FILE SEGMENT: BA

LANGUAGE: CHINESE

ENTRY DATE: Entered STN: 5 Sep 1987

Last Updated on STN: 5 Sep 1987

AB N-deacetyllappaconitine (DLA) 1-10 mg/kg or lappaconitine (LA)

1-6 mg/kg inhibited several inflammatory processes, such as increase of capillary permeability due to ip 0.7% acetic acid 10 mg/kg in mice: ear swelling induced by xylene in mice: edema produced by injecting 1% carrageenin 0.15 ml or fresh egg white 0.1 ml beneath the planter surface of hind paw in rats and the growth of rat granuloma caused by cotton pellets, without influencing the weights of thymus and adrenal. Their anti-inflammatory activity was also demonstrated in adrenalectomized rats. DLA and LA neither prolonged the surviving time of adrenalectomized rats nor reduced the content of adrenal ascorbic acid in These results suggest that the anti-inflammatory actions of DLA and LA do not depend on stimulation of the pituitary-adrenal axis. The hot plate, formaldehyde and HAc-writhing tests in mice showed that DLA and LA had a marked analgesic action, their sc median analgesic doses (ED50) were 7.1, 3.8 mg/kg and 2.3, 3.5 mg/kg in mice with formaldehyde and HAc-writhing test, respectively. DLA exhibited marked local anesthetic activity as shown by sciatic nerve block in mice, its ED50 concentration was 0.076%. DLA 15 mg/kg and LA 6 mg/kg ip showed an antipyretic effect in rats with fever induced by sc injection of 7% yeast 3 ml/kg. The ip LD50 of DLA and LA were 23.5, 10.5 mg/kg (mice) and 29.9, 9.9 mg/kg (rats), respectively.

ANSWER 18 OF 23 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. L2STN **DUPLICATE 8**

ACCESSION NUMBER: 1987:319988 BIOSIS

DOCUMENT NUMBER: PREV198784039495; BA84:39495

TITLE:

STUDIES ON THE ANALGESIC ACTION AND PHYSICAL DEPENDENCE OF

BULLEYACONITINE A.

AUTHOR (S): TANG X-C [Reprint author]; LIU X-J; LU W-H; WANG M-D; LI

CORPORATE SOURCE: SHANGHAI INST MATERIA MED, CHINESE ACAD SCI, SHANGHAI

SOURCE: Yaoxue Xuebao, (1986) Vol. 21, No. 12, pp. 886-891.

CODEN: YHHPAL. ISSN: 0513-4870.

DOCUMENT TYPE: Article

FILE SEGMENT: BA LANGUAGE: CHINESE

ENTRY DATE: Entered STN: 25 Jul 1987

Last Updated on STN: 25 Jul 1987

AB Aconitum bulleyanum Diel is an herb which has been used as an anodyne in Yunnan province for a long time. Bulleyaconitine A (Bul), an active principle, was extracted from this herb. The analgesic action of Bul has been shown in this paper by using the following methods: mice writhing evoked by ip 0.7% acetic acid 10 ml/kg; mice hot plate (56°C); continuous pain stimuli elicited by sc formaldehyde in front paw(8) and rat tail-flick response to light irradiation. The relative analgesic effect of Bul was found to be 1.8 .apprx. 3.25, 15.3 .apprx. 65.5 and 1203 .apprx. 7195 times as potent as 3acetylaconitine, morphine and aspirin, respectively. The duration of analgesic effect of Bul assayed with pain stimuli of formaldehyde in mice was longer than that of morphine. No tolerance of analgesic effect was found after daily sc of Bul 0.15 mg/kg for 9 d in mice assayed with hot plate method. In nalorphine-challenge test, no jumping response was observed in mice treated with Bul 1.2 mg/kg, the maximal tolerance dose. Rats were given sc morphine 25 mg/kg bid for 120 d, withdrawal of morphine was followed by a decrease in body weight, which was used as a parameter of abstinence syndrome, Bul sc 0.1 mg/kg did not alter the weight loss of morphine-treated rats. One male monkey developed physical dependence after sc morphine of which the daily dose was increased progressively from 2.5 to 25 mg/kg in 21 d and then maintained for 120 d. Bul 30 $\mu g/kg$ sc did not suppress the withdrawal signs evoked by ip nalorphine 0.5 mg/kg. The results indicate that Bul induced no morphine-like tolerance nor physical dependence. The analgesic action of Bul was not antagonized by naloxone, but was eliminated by intraperitoneal injection of reserpine 3 mg/kg 3 h prior to Bul. The antagonistic action of reserpine to Bul could be reversed by icv 5-HT or